Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal

Khabirov F.A.; Babicheva N.N.; Khaĭbullin T.I.; Aver'ianova L.A.; Granatov E.V.; Akhmedova G.M.

doi:https://doi.org/

Khabirov F.A.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Babicheva N.N.

Khaĭbullin T.I.

Aver'ianova L.A.

Granatov E.V.

Akhmedova G.M.

Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal

Authors:

Khabirov F.A., Babicheva N.N., Khaĭbullin T.I., Aver'ianova L.A., Granatov E.V., Akhmedova G.M.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(9‑2): 113‑122

Read: 1700 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Khabirov FA, Babicheva NN, Khaĭbullin TI, Aver'ianova LA, Granatov EV, Akhmedova GM. Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(9‑2):113‑122. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Cognitive impairment in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73

Molecular mechanisms of acute disseminated encephalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11

The role of monocytes in the immunopathogenesis of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27

Results of a 5-year project for the early diagnosis of multiple sclerosis in first-line blood relatives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33

Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple sclerosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38

Features of the clinical course of multiple sclerosis as a factor in persistent disability. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44

Quantitative analysis of cerebrospinal fluid flow in multiple sclerosis patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):45-50

A clinical case of X-linked adrenoleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107

Biosimilars of ranibizumab in retinal diseases: new possibilities in ophthalmology. Russian Annals of Ophthalmology. 2025;(2):106-116

Artificial intelligence capabilities in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21

Abstract:

The results of using ronbetal, the Russian biosimilar of interferon-beta 1b, in the treatment of multiple sclerosis (MS) are presented. The study included outpatients followed up from February 2008 to March 2012. All patients were assessed neurologically with additional evaluation using the EDSS; a number of exacerbations and their outcomes, disease progression, tolerability of the drug were recorded. No significant differences in the efficacy of ronbetal and betaferon were found. The frequency of exacerbations and MS progression were comparable for both drugs. The same was with the tolerability, with the exception of higher frequency of the flu-like syndrome at the beginning of treatment with ronbetal. A single-step substitution of betaferon for ronbetal often caused the discontinuation of treatment by patients because they were not fully informed about the new drug, need to use a new dose titration scheme and were anxious about side-effects.

Keywords:

multiple sclerosis

interferon-beta 1b

biosimilar

ronbetal